Evidence map›Paper›PMID 33824285›Full record

ArticleCell death & disease2021

TFAP2A potentiates lung adenocarcinoma metastasis by a novel miR-16 family/TFAP2A/PSG9/TGF-β signaling pathway.

Yanlu Xiong, Yangbo Feng, Jinbo Zhao, Jie Lei, Tianyun Qiao, Yongsheng Zhou, Qiang Lu, Tao Jiang, Lintao Jia, Yong Han

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Translational lung cancer research · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yanlu XiongDepartment of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.ORCID 0000-0002-9026-5488
Yangbo FengDepartment of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Jinbo ZhaoDepartment of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Jie LeiDepartment of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Tianyun QiaoDepartment of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Yongsheng ZhouDepartment of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Qiang LuDepartment of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Tao JiangDepartment of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. jiangtaochest@163.com.ORCID 0000-0002-5848-1922
Lintao JiaState Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an, China. jialth@fmmu.edu.cn.ORCID 0000-0001-6329-0453
Yong HanDepartment of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. hanyong_td@163.com.ORCID 0000-0002-5325-1722
Air Force Medical University · CNAir Force General Hospital PLA · CNTang Du Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcription factor AP-2α (TFAP2A) was previously regarded as a critical regulator during embryonic development, and its mediation in carcinogenesis has received intensive attention recently. However, its role in lung adenocarcinoma (LUAD) has not been fully elucidated. Here, we tried to investigate TFAP2A expression profiling, clinical significance, biological function and molecular underpinnings in LUAD. We proved LUAD possessed universal TFAP2A high expression, indicating a pervasively poorer prognosis in multiple independent datasets. Then we found TFAP2A was not indispensable for LUAD proliferation, and exogenous overexpression even caused repression. However, we found TFAP2A could potently promote LUAD metastasis possibly by triggering epithelial-mesenchymal transition (EMT) in vitro and in vivo. Furthermore, we demonstrated TFAP2A could transactivate Pregnancy-specific glycoprotein 9 (PSG9) to enhance transforming growth factor β (TGF-β)-triggering EMT in LUAD. Meanwhile, we discovered suppressed post-transcriptional silencing of miR-16 family upon TFAP2A partly contributed to TFAP2A upregulation in LUAD. In clinical specimens, we also validated cancer-regulating effect of miR-16 family/TFAP2A/PSG9 axis, especially for lymph node metastasis of LUAD. In conclusion, we demonstrated that TFAP2A could pivotally facilitate LUAD progression, possibly through a novel pro-metastasis signaling pathway (miR-16 family/TFAP2A/PSG9/ TGF-β).

Indexed as

Adenocarcinoma of LungCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansLung NeoplasmsLymphatic MetastasisMicroRNAsNeoplasm MetastasisTranscription Factor AP-2Up-RegulationMicroRNAsMIRN16 microRNA, humanTFAP2A protein, humanTranscription Factor AP-2

Identifiers

PMID33824285
PMCPMC8024312
OpenAlexW3139802259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.